Overview Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (CAR-T) in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201 (NXC-201), currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a NEXICART-1 (NCT04720313) clinical trial. NEXICART-2 is expected to enroll 40 patients, with f...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001493152-26-012714 | EDGAR | 74K words |
| 2025-03-25 | 2024-12-31 | 0001641172-25-000387 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001493152-24-011975 | EDGAR | — |
| 2023-03-27 | 2022-12-31 | 0001493152-23-009091 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001493152-22-007921 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001493152-25-021325 | EDGAR | 28K words |
| 2025-08-08 | 2025-06-30 | 0001641172-25-022829 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001641172-25-009280 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044787 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001493152-24-031358 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018458 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040182 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001493152-23-027844 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016721 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001493152-22-031101 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001493152-22-022359 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013365 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001493152-26-013663 | EDGAR | 1K words |
| 2026-03-25 | 0001493152-26-012721 | EDGAR | — |
| 2025-12-08 | 0001493152-25-026697 | EDGAR | — |
| 2025-12-08 | 0001493152-25-026500 | EDGAR | — |
| 2025-11-26 | 0001493152-25-025182 | EDGAR | — |
| 2025-09-08 | 0001493152-25-012804 | EDGAR | — |
| 2025-06-23 | 0001641172-25-016120 | EDGAR | — |
| 2025-06-03 | 0001641172-25-013417 | EDGAR | — |
| 2024-07-26 | 0001493152-24-029174 | EDGAR | — |
| 2024-07-22 | 0001493152-24-028595 | EDGAR | — |
70 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001873835 |
| Ticker | IMMX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.immixbio.com |
| Listed | 2021-12-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report